Takeda

This phase 3 trial is testing whether a new formulation of Takeda's dengue vaccine (TDV) works as well as the current approved version. About 496 healthy adults aged 18-60 who have never had dengue will receive two shots three months apart. The main goal is to compare immune resp…

This study follows 75 adults who have had a stem cell or solid organ transplant and are being treated with maribavir for cytomegalovirus (CMV) infection. Researchers will track how well the drug clears the virus, how long treatment lasts, and any side effects. The goal is to see …

This phase 3 trial tests a drug called teduglutide in 13 Chinese adults with short bowel syndrome who rely on IV nutrition. Participants get a daily injection for 24 weeks to see if it reduces their need for IV support. The study also checks safety and how the body processes the …

This study tests whether TAK-861 can control symptoms of narcolepsy type 1, a condition causing sudden sleep attacks and muscle weakness. About 88 adults will take TAK-861 for several months, then some will switch to a placebo to see if symptoms return. The goal is to see if the …

This study tests an oral drug called TAK-279 (Zasocitinib) in 207 adults with moderate-to-severe ulcerative colitis. Participants take either the drug or a placebo for 12 weeks, then everyone gets the drug for up to a year. The goal is to see if TAK-279 reduces bowel inflammation…

This study follows 155 people in Japan with hereditary angioedema (HAE) who are taking TAKHZYRO (lanadelumab) injections every two weeks. Researchers will monitor side effects and check if the drug helps control swelling attacks over 12 months. The goal is to see how well TAKHZYR…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests whether giving vedolizumab every 4 weeks instead of every 8 weeks can help Japanese patients with moderate to severe ulcerative colitis or Crohn's disease whose symptoms returned during standard treatment. About 56 participants will receive the drug intravenously…

This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…

This study is checking the long-term safety and side effects of an experimental pill called TAK-279 in about 2,100 adults with moderate-to-severe plaque psoriasis. All participants will take the drug for up to 4 years, with regular clinic visits. The goal is to see how well peopl…

This study tests whether vedolizumab, given as an IV infusion, can help Chinese adults with moderate to severe ulcerative colitis. About 392 participants will receive either the drug or a placebo. The goal is to see if it reduces symptoms like diarrhea and bleeding, and helps ach…

This study tests an oral drug called mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take the drug daily for up to a year or longer if their cancer s…

This study tests the long-term safety of TAK-881, a subcutaneous immunoglobulin treatment, in 53 adults and children with primary immunodeficiency diseases (PIDD) who completed a prior study. Participants receive regular infusions every 2-4 weeks and are monitored for side effect…

This study tests a medicine called TAK-755 in people with a rare inherited blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP). The condition causes dangerous blood clots and bleeding. TAK-755 replaces a missing enzyme to help prevent or treat these episod…

This phase 3 trial compares a new oral targeted drug, TAK-788 (mobocertinib), against standard chemotherapy as a first treatment for advanced non-small cell lung cancer with a specific EGFR mutation (exon 20 insertion). About 354 adults with this rare mutation will be randomly as…

This phase 2 trial is testing an experimental cell therapy called TAK-007 in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections o…

This study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…

This expanded access program offers fruquintinib, a targeted cancer drug, to adults with metastatic colorectal cancer that has worsened after all standard treatments. Participants take the drug as a capsule daily for three weeks, then one week off. The goal is to provide access u…

This study aimed to see if giving a combination of immune-suppressing drugs (rituximab, methotrexate, and IVIG) alongside the standard enzyme therapy ELAPRASE could prevent patients with Hunter syndrome from developing harmful antibodies. It was designed for boys who had never re…

This phase 3 trial tests whether ponatinib (Iclusig) works better than imatinib (Gleevec) for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Both drugs are taken as pills alongside reduced-intensity chemotherapy for up to 20 m…

This study tested a new drug combination (brentuximab vedotin plus standard chemotherapy) in 59 children with advanced, newly diagnosed Hodgkin lymphoma. The goal was to find the safest dose and see how well it shrinks tumors. Early results show many children achieved complete re…

This study is a follow-up for people with Hunter syndrome and cognitive problems who already took part in earlier studies. It aims to check the long-term safety of the drug idursulfase-IT given with Elaprase. About 6 children and adults will continue their same treatment to monit…

This study checks the long-term safety of a drug called fazirsiran in people with liver disease caused by alpha-1 antitrypsin deficiency. About 31 adults who were in earlier studies can keep getting the drug every 3 months. The goal is to see if fazirsiran is safe over time and i…

This study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a g…

This study aims to find out how many people in Spain have been diagnosed with narcolepsy type 1 or type 2, and how many new cases are diagnosed each year. Researchers will review medical records from hospitals across Spain to count patients and understand patterns. No treatment o…

This phase 1 trial is testing whether soticlestat, an experimental drug, has any effect on heart rate or rhythm. Healthy adult volunteers will receive multiple doses of soticlestat, a placebo, or an active control, and their heart activity will be monitored continuously via ECG. …

This observational study aims to measure how many people in Portugal have Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS), two rare and severe forms of epilepsy. Researchers will review existing medical records from about three public hospitals to estimate the percentage of…

This study looks at how a tool called CDPATH can help predict the risk of serious complications in people with Crohn's disease within the next three years. About 200 adults with Crohn's will use the tool to learn their risk level (low, medium, or high) and discuss treatment optio…

This study follows pregnant women with chronic constipation who took the drug prucalopride and compares them to those who did not. Researchers track health outcomes for mothers and infants for one year after birth to see if the drug is linked to birth defects or other problems. N…

This study tracks side effects and severe dengue cases in 2,000 people who already got the QDENGA dengue vaccine in Malaysia. No new vaccine is given—researchers simply collect health data from participants. The goal is to understand real-world safety and whether vaccinated peopl…

This study observes 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months and receive standard care. The goal is to better understand relapse timing in real-life practice,…

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug in everyday hospital settings. No new treatment …

This study analyzes tumor genes from 757 patients with advanced colorectal cancer to find markers that predict how well they respond to two different chemotherapy combinations. Participants receive either mFOLFOX6 plus bevacizumab or mFOLFOX6 plus panitumumab. The goal is not to …

This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes th…

This study looks at gene changes in tumor tissue from 787 people with advanced or recurrent colorectal cancer who took part in an earlier treatment study. Researchers want to see if certain genes are linked to how long patients lived or how long their cancer stayed under control.…

This study uses insurance claims data to see if taking the constipation drug prucalopride during pregnancy is linked to birth defects or other problems for mothers and babies. Researchers will compare pregnant women who took prucalopride, those who took other constipation medicin…

This study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside o…